Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

150%

3 of 2 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2
1(33.3%)
Phase 1
1(33.3%)
Phase 3
1(33.3%)
3Total
Phase 2(1)
Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04104321Phase 3Suspended

A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)

Role: lead

NCT04480827Phase 1Completed

Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment

Role: lead

NCT02279524Phase 2Completed

A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH

Role: lead

All 3 trials loaded